key: cord-0693210-btxa0tps
authors: Zheng, Dahai; Chen, Gang; Guo, Beichu; Cheng, Genhong; Tang, Hong
title: PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production
date: 2008-10-28
journal: Cell Res
DOI: 10.1038/cr.2008.294
sha: e4c652c4a46487521e7430370fa6fd7d7d9a3e1d
doc_id: 693210
cord_uid: btxa0tps

Infections by coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) result in very little type I interferon (IFN) production by host cells, which is potentially responsible for the rapid viral growth and severe immunopathology associated with SARS. However, the molecular mechanisms for the low IFN production in cells infected with coronaviruses remain unclear. Here, we provide evidence that Papain-like protease domain 2 (PLP2), a catalytic domain of the nonstructural protein 3 (nsp3) of MHV-A59, can bind to IRF3, cause its deubiquitination and prevent its nuclear translocation. As a consequence, co-expression of PLP2 strongly inhibits CARDIF-, TBK1- and IRF3-mediated IFNβ reporter activities. In addition, we show that wild-type PLP2 but not the mutant PLP2 lacking the deubiquitinase (DUB) activity can reduce IFN induction and promote viral growth in cells infected with VSV. Thus, our study uncovered a viral DUB which coronaviruses may use to escape from the host innate antiviral responses. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/cr.2008.294) contains supplementary material, which is available to authorized users.

The coronavirus family has been extensively studied since the severe acute respiratory syndrome (SARS) broke out in 2003 [1] . SARS coronavirus (SCoV) belongs to the group II coronavirus and is phylogenetically related to the mouse hepatitis virus A59 (MHV-A59) [2] . Studies showed that type I interferons (IFNs) including IFNα and IFNβ could inhibit replication of SCoV, and IFNβ was more effective [3, 4] . However, clinical studies revealed that SCoV infection induced very low levels of type I IFNs [5] [6] [7] , which likely contributed to the rampant viral replication and high mortality associated with the disease. Interestingly, a similar type I IFN response was also found in MHV-A59 infection [8, 9] . It was reported recently that certain viral components of SCoV, such as nsp1, nsp3 (nonstructural protein 3), ORF3b, ORF6 and N protein, might play some roles in the inhibition of type I IFN induction [10, 11] . However, the underlying molecular mechanisms remain to be elucidated.

Type I IFNs (mainly IFNβ and multiple IFNα subtypes) are believed to be the most important cytokines in innate immunity against viral infections. Depending upon the nature of invading viruses and the infected host cell types, Toll-like receptors (TLRs) such as TLR3, 7 and 9, as well as cytosolic RNA helicases, such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA-5), play important roles of sentinel to recognize viral genomes and trigger the type I IFN signaling through adaptor proteins TRIF, MyD88 or CARDIF [12] [13] [14] [15] . Moreover, recent studies indicate that these multiple TLR-dependent and -independent pathways may converge on a common TRAF3 adaptor complex, leading to the activation of two critical serine/threonine kinases, TBK1 or IKKε [16, 17] . Activated TBK1 or IKKε then phosphorylates the transcription factor IRF3, which translocates into the nucleus to activate the transcription of type I IFN genes. Secreted IFNs, via autocrine or paracrine circuit, activate the JAK-STAT pathway through the common type I interferon receptor (IFNAR) and induce the expression of an array of anti-viral related genes and cytokines [18, 19] .

Recent research also indicates that host cells possess intrinsic ubiquitination and deubiquitination programs that are critically involved in the type I IFN induction pathway [20, 21] . Interestingly, the nonstructural protein of SCoV, nsp3, a known protease involved in the processing of replicase polyproteins, has recently been shown to carry a conserved deubiquitinase (DUB) motif within its papain-like protease (PLpro) domain [22] . In the present study, we provide evidence showing that nsp3 of MHV-A59, a group II coronavirus phylogenetically related with SCoV, can efficiently inhibit IRF3 ubiquitination and IFN induction. This novel finding therefore sheds new light into why host cells produce very low levels of type I IFNs characteristic for innate immunity evasion by SCoV and MHV [5] [6] [7] [8] [9] . These results also suggest a novel target for the development of drugs against SARS.

Using Sendai virus (SeV) as a control, we assessed whether MHV-A59 induced IFNβ expression in mouse embryonic fibroblasts (MEFs). Quantitative RT-PCR analyses showed rapid and strong IFNβ production in response to SeV infection of MEF cells (6 h post-infection), whereas MHV-A59 infection resulted in no detectable IFNβ induction along the time course, with trivial increase after 24 h of infection ( Figure 1A ). MHV-A59 replicated well in MEFs as revealed by the RT-PCR assay showing the expression of nucleocapsid genes and the plaque assay (Supplementary information, Figure S1 ). IFNβ binds to IFNAR to activate the phosphorylation of STAT1. The inability of MHV-A59 to effectively induce IFNβ gene expression correlated well with undetectable STAT1 phosphorylation, as compared with strong STAT1 phosphorylation after SeV infection ( Figure 1B ). IRF3 is a nucleo-cytoplasm shuttling factor that requires phosphorylation and dimerization for transcriptional activation. In contrast to SeV, MHV-A59 infection of MEFs could induce neither dimerization ( Figure 1C ) nor nuclear translocation ( Figure 1D ) of IRF3. These results The data were normalized to that of 18s RNA and averaged as fold activation over that by mock infection (mean±SD). (B) STAT1 was not phosphorylated after MHV-A59 infection. Whole cell lysates (15-20 µg) after virus infections at the indicated time points were subject to 10% SDS-PAGE and phosphorylated STAT1 was immunoblotted. Total STAT1 was also detected as a loading control. (C) IRF3 was not activated by MHV-A59. Whole cell lysates (15-20 µg) after virus infections for the indicated time points were subject to 10% native PAGE and IRF3 dimerization was immunoblotted with anti-IRF3 antibody. β-Actin was immunoblotted as a loading control. (D) IRF3 did not translocate to the nucleus. Nuclear extracts (15 µg) from the infected MEFs were resolved in 10% SDS-PAGE and the presence of IRF3 was immunoblotted similarly to (C). USF2 and β-tubulin were immunoblotted as a loading control or to exclude contamination of the extracts, respectively. The data represented at least 3 independent experiments. 1108 npg therefore suggest that host cells lack the ability to produce type I IFN in response to MHV-A59 infection.

Because ubiquitination plays an important role in the RIG-I-mediated IFN induction cascade [20] , and because PLpro domain 2 (PLP2) domain of MHV-A59 contains a conserved DUB motif [22] , we hypothesized that the DUB activity of PLP2 domain might block the IFNβ response during MHV-A59 infection. As the first step to identify the potential target of PLP2 DUB in the type I IFN signaling pathway, we tested whether IFN reporter activities driven by overexpressed CARDIF, TBK1 or IRF3 were affected by co-expressed PLP2. As shown in Figure 2A -C, PLP2 efficiently inhibited IFNβ reporter activities in a dosedependent manner (data not shown for expression of various exogenous proteins). As mentioned above, PLP2 is the main active domain of nsp3; to understand whether full-length nsp3 also contains such activity we tried to clone the full-length nsp3 of MHV-A59. However, the full-length sequence appears very unstable, always resulting in smaller inserts in our constructs. We were able to We found that this construct could produce a 150-kDa protein and could greatly inhibit the type I IFN signaling pathway (Supplementary information, Figure S2 ). At the same time, we also tested the effect of full-length nsp3 of ScoV, which is a close relative of MHV-A59. Expression of this construct could produce several proteins with different sizes and could also inhibit the type I IFN signaling pathway (Supplementary information, Figure S3 ). Because PLP2 exhibited apparent inhibition of IRF3-driven reporter activity, and IRF3 activation is the very last step in the type I IFN signaling pathway, we suspected that inhibition of IRF3 ubiquitination by PLP2 DUB would account for the inactivation of IRF3 and reduced IFNβ production. While overexpressed IRF3 became poly-ubiquitinated, such polyubiquitin modification of IRF3 was effectively inhibited by co-expressed PLP2 DUB ( Figure 3A) . Furthermore, PLP2 could deconjugate both Lys63-and Lys48-linked polyubiquitin chains as shown with the mutant Ubi-K48 or Ubi-K63 (described in Materials and methods), respectively ( Figure 3B ), suggesting its rather promiscuous spectra of deubiquitination. This result was also in good agreement with its general hydrolyzing activity towards cellular polyubiquitinated proteins (data not shown). Furthermore, Flag-PLP2 and Myc-IRF3 were reciprocally co-immunoprecipitated with each other, indicating that they could form a complex ( Figure 3C ). All these data therefore suggest that PLP2 likely inhibited IFN induction through binding to and deubiquitinating IRF3.

The Cys residue of the catalytic triad "Cys-His-Asp" is essential for the DUB activity of SCoV PLpro domain [22] . blocked SeV-induced IRF3 nuclear translocation. Nuclear translocation of endogenous IRF3 after SeV infection of HEK293T cells transiently expressing PLP2 or PLP2-C106A was monitored as that in Figure 1D , and expression level of constructs and IRF3 were also measured in cytosolic extracts. (C) Inactivated PLP2 DUB failed to inhibit VSV-induced IFNβ production. HEK293T cells transiently transfected with PLP2 or PLP2-C106A were infected with VSV (MOI=0.1) for 5 h and mRNA levels of endogenous IFNβ were measured by quantitative real-time PCR as those in Figure 1A , except that PCR primers specific to human IFNβ gene were used and GAPDH expression was used for normalization. Data were expressed as the fold activation for each sample by dividing the luciferase activity by that observed in the uninfected sample (mean±SD). (D) PLP2 DUB inhibited VSV replication. The supernatants from cells as treated in (C) were collected for plaque assays to determine the virus titer. The data represented at least 3 independent experiments. When we mutated the conserved Cys106 to Ala, the resultant mutant (PLP2-C106A) could no longer deubiquitinate IRF3 ( Figure 4A ). In the following experiments we found that the C106A mutant showed reduced ability to inhibit IFNβ promoter activation driven by CARDIF, TBK1 and IRF3 ( Figure 4B-4D) . We also produced another mutant, PLP2-D277A (Asp277 to Ala), which changes one of the catalytic triad, Asp277. Unexpectedly, the D277A mutant still showed strong DUB activity ( Figure 4E ) even though its expression level was lower. Consequently, D277A could still inhibit the activation of IFNβ promoter ( Figure 4F ). Therefore, our data indicate that the DUB activity of PLP2 was required for the inhibition of type I IFN induction.

IRF3 activation has been shown to be critically involved in type I IFN induction by paromyxoviruses such as SeV and VSV [23, 24] . In order to substantiate our hypothesis that PLP2 DUB may be a general blocker of the type I IFN signaling pathway, we set to determine whether PLP2 inhibits IFN production induced by these viruses. Overexpression of wild-type PLP2 could greatly inhibit the activation of IFNβ promoter induced by SeV infection of HEK293T cells, while PLP2-C106A failed to do so ( Figure 5A ). The ability of PLP2 to inhibit IFNβ induction by SeV ( Figure  5A ) was due to inactivation of IRF3, as wild-type PLP2 but not the PLP2-C106A mutant inhibited IRF3 nuclear translocation ( Figure 5B) . Similarly, wild-type PLP2 but not PLP2-C106A could effectively inhibit VSV-mediated induction of endogenous IFNβ mRNA ( Figure 5C ) and, consequently, accelerate virus replication in HEK293T cells ( Figure 5D ). Overall, it is tempting to speculate that group II coronaviruses, including MHV-A59 and SCoV, might utilize the immediate-early gene product, nsp3, to subvert host anti-viral innate immune response by preventing ubiquitination and activation of IRF3, a critical transcription factor in the type I IFN signaling pathway.

Coronaviruses are able to infect a broad range of vertebrates to evoke systemic immunopathological dysfunction. Lack of type I IFN production in host cells to effectively control viral replication likely plays an important role in SARS manifestation and progression. By using a mousespecific strain of group II coronavirus, MHV-A59, we provide evidence here that a DUB activity conserved among coronavirus nsp3 proteins might specifically inhibit IRF3 activation, and thereby is responsible for viral inhibition of cellular type I IFN production.

Most mammalian cells including immune and non-immune cells can produce type I IFNs in response to various viral infections. On the other hand, as a result of hostpathogen co-evolution, viruses have developed various strategies to escape from type I IFN response. For example, VP35 of Ebola virus could inhibit the phosphorylation of IRF3 [25] ; NS1 of influenza virus could bind dsRNA and inhibit the subsequent activation of IRF3 [26] . NS34A, a cysteine protease of HCV, could cleave CARDIF to block RIG-I-mediated IFN induction [27] . In immune response to SARS-CoV and other coronaviruses, such as HCoV-OC43, there is an unusual lack of the antiviral IFN response [5] [6] [7] [8] . The finding that MHV-A59 PLP2 potently inhibits IRF3 ubiquitination ( Figure 3 ) and its transcriptional activation of the IFNβ gene (Figures 2, 4 and 5) provides novel insight into how the viral gene expression program targets the host innate immune system. During our study, another group reported a similar phenomenon that SCoV PLpro could block IRF3-mediated type I IFN induction [28] . However, in their study, they concluded that the DUB activity of PLpro was not involved in the inhibition of type I IFN signaling pathway because the Asp mutant (D1826A), which had been shown to lose >99% of DUB activity [22] , could still inhibit type I IFN induction [28] . In our present study, we found that the Asp mutant of PLP2 could still strongly block the ubiquitination of IRF3 ( Figure 4B ). In fact, from the data of the previous study [22] , one could clearly see that the D1826A mutant could cleave di-ubiquitin to produce mono-ubiquitin, even though its activity was lower than that of WT. Considering the situation of over-expression, the remaining DUB activity might be sufficient to affect the ubiquitination process of the cells. Therefore, we propose that the DUB activity of PLP2 is closely related to its function to block the type I IFN induction pathway.

A growing body of evidence indicates that ubiquitination is critically involved in the type I IFN signaling pathway. Ubiquitination of RIG-I by the E3 ubiquitin ligase TRIM25 is necessary and sufficient to trigger the downstream signaling cascade to produce type I IFNs [20] . Ubiquitination of IRF7 by the E3 ligase TRAF6 has been implicated in type I IFN induction in TLR7, 8 and 9 pathways [29, 30] . Studies have shown that activated IRF3 could be polyubiquitinated and degraded [31, 32] , yet one could not exclude the possibility of IRF3 activation by ubiquitination just like what is observed with RIG-I [20] . In the present study we found that IRF3 could be ubiquitinated by both K48 and K63 Ubi ( Figure 3B) . Notably, K48 ubiquitination is involved in degradation while K63 ubiquitination is usually regarded as an active form of ubiquitin-targeted proteins [33, 34] . The fact that deubiquitinated IRF3 fails to translocate to the nucleus ( Figure 5B ) also supports the possibility that IRF3 activation may require ubiquitination. Although further studies are needed to elucidate the relationship between www.cell-research.com | Cell Research Dahai Zheng et al. 1111 npg the activation and ubiquitination of IRF3, our present study and the recent report by others [28] clearly show that IRF3 is a target of the coronavirus PLpro. Interestingly, the newly identified cellular DUB, DUBA, inhibits the ubiquitination of TRAF3, an adaptor of RIG-I signaling, and negatively regulates the type I IFN signaling pathway [21] . Coronaviruses may have picked up this mechanism from the host during their co-evolution, and deubiquitination of IRF3 by nsp3 seems to provide a general suppression of anti-viral IFN production to facilitate productive infection. This strategy is not unique to viruses because the bacterial virulence factor YopJ also functions as a DUB that inhibits TRAFsmediated innate immune response [35] . It would be ideal to provide definitive evidence that nsp3PLP2 encodes a functionally important DUB by either reverse genetics to introduce point mutations (e.g., C106A) into the MHV-A59 genome [36] or small interference RNA against nsp3 to rescue IFN response in the infected cells. However, the nsp3 protein and the catalytic cysteine site are required for the processing of replicase polyprotein of coronaviruses [22, 37] ; therefore targeting of nsp3 would affect viral replication per se. Nevertheless, ectopic expression of the PLP2 domain inhibits both SeV-and VSV-induced IFN response and facilitates viral replication ( Figure 5 ), suggesting that MHV-A59 PLP2 provides a general inactivation mechanism of the host anti-viral response through deubiquitination of important innate immunity regulatory factor(s), such as IRF3.

Taken together, the results of our study and others suggest that inactivation of IRF3 by nsp3 may contribute to the weak IFN response in coronavirus infections. Ultimate understanding of the overall interactions between coronaviruses and the host innate immune system will provide further insight into the pathogenesis of viruses in this class, and open a new avenue of therapeutic target exploration against coronavirus infections.

Wild-type MEF cells were in C57/BL6 background. The cell lines L929, HEK293T and HeLa were routinely maintained in DMEM (Hyclone, UT, USA) supplemented with 10% FCS (PAA, Pasching, Austria) and 1% penicillin and streptomycin (Hyclone, UT). Cell line 17Cl-1 is a kind gift from Dr K Holmes (University of Colorado Health Sciences Center, USA). The constructs pEBB-HA-TBK1 and pcDNA3.1-CARDIF were described previously [17, 38] . Wild-type ubiquitin expression vector pRK5-HA-Ubi and the mutant derivatives Ubi-K63 and Ubi-K48 were from Dr K Lim (National Neuroscience Institute, Singapore); the K63 or K48 mutant contains arginine substitutions on all of the lysine residues except the one at position 63 or 48, respectively [39] . Primer pairs specific to MHV-A59 N protein gene were forward: 5′-CAA AGA AAA GGG CGT AGA CAG G-3′ and reverse: 5′-CGC CAT CAT CAA GGA TCT GAG-3′. Full-length human IRF3 sequence was subcloned into the vector pFLAG-CMV-2 between EcoRI and SalI sites. MHV-A59 PLP2 domain (nt 1-1 080) was RT-PCR amplified from MHV-A59-infected cells and subcloned into pCMV-Myc plasmid between EcoRI and XhoI sites. PCR primers were derived from the MHV-A59 genome sequence (NCBI NC_001846, nt 5 040-6 119): forward 5′-CGG AAT TCG GGT TGA TGT CTT GTG TAC TG-3′ and reverse 5′-CCG CTC GAG TTA CAA TTT AAA GTT GGT ATA GAC-3′. Point mutagenesis was performed according to the described protocol [40] . 

MHV-A59 kindly provided by Dr Lishan Su (University of North Carolina, USA) was expanded in 17Cl-1 cell and purified as described previously [41] . The titer of the virus was determined by plaque assay in 17Cl-1 cells exactly as described [42] and MOI = 5 was used for the infection.

SeV was from the Wuhan Inst Virol, CAS, China and expanded in day 10 embryonate eggs. The allantoic fluid was harvested 72 h after inoculation. The viral titer was measured for hemagglutination (HA) with chicken erythrocytes using the pattern method [43] . The HA titer was expressed as the highest dilution of the allantoic fluid showing complete HA. The HA titer of SeV stock was 1:256, and for infection 1:25 was used.

Vesicular stomatitis virus (VSV) was provided by Dr G Gao (Institute of Biophysics, CAS, China). The virus was expanded in L929 cells and titrated with plaque assay in HeLa cells as that of MHV. MOI = 0.1 was used for infection.

Total RNA extraction by Trizol (Invitrogen, CA, USA) and quantitative real-time PCR reactions in a MyiQ cycler (Bio-Rad, CA, USA) using SYBR Green I (Molecular Probes, OR, USA) were performed exactly as described previously [44] . The primer pairs for mouse IFNβ and 18s RNA were derived from previous reports [44, 45] . The primer pairs for human IFNβ and GAPDH were IFNβ forward: 5′-AAA CTC ATG AGC AGT CTG CA-3′; IFNβ reverse: PLP2 from MHV inhibits type I IFN response Cell Research | Vol 18 No 11 | November 2008 1112 npg 5′-AGG AGA TCT TCA GTT TCG GAG G-3′; GAPDH forward: 5′-AAG CTC ACT GGC ATG GCC TT-3′; GAPDH reverse: 5′-AGG AGA CCA CCT GGT GCT CAG-3′. The mRNA levels of indicated genes were normalized to that of 18s RNA or GAPDH mRNA. The data represented the average of at least three independent experiments (mean±SD).

Transient transfection of HEK293T cells with indicated plasmids was performed routinely with calcium phosphate method. Co-immunoprecipitation [46] and nuclear Western blotting [44] were performed exactly as described previously.

IRF-3 activation was assessed by its ability to homodimerize using native PAGE precisely as described previously [47] .

IFNβ luciferase reporter plasmid described previously [48] was co-transfected with the indicated constructs into HEK293T cells. Renilla luciferase plasmid was co-transfected as internal control of transfection efficiency. Luciferase activities were measured and normalized as per instructions by the manufacturer (Dual-Luciferase reporter assay system, Promega, WI). Luciferase activities were measured 24 h after transfection or after cells were infected by SeV for an additional 8 h.

A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Treatment of SARS with human interferons

Potent inhibition of SARSassociated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma)

Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome

The immunobiology of SARS*

SARS coronavirus and innate immunity

Mouse hepatitis virus does not induce Beta interferon synthesis and does not inhibit its induction by doublestranded RNA

Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition

Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain

Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists

Toll-like receptors and innate immunity

The host type I interferon response to viral and bacterial infections

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter

Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response

Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif

Triggering the interferon response: the role of IRF-3 transcription factor

IRF family of transcription factors as regulators of host defense

TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity

DUBA: a deubiquitinase that regulates type I interferon production

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Cell type-specific involvement of RIG-I in antiviral response

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3

Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6

Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination

Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1

Involvement of the IkappaB kinase (IKK)-related kinases tank-binding kinase 1/IKKi and cullin-based ubiquitin ligases in IFN regulatory factor-3 degradation

Ubiquitin: structures, functions, mechanisms

Molecular determinants of polyubiquitin linkage selection by an HECT ubiquitin ligase

YopJ targets TRAF proteins to inhibit TLR-mediated NF-kap-paB, MAPK and IRF3 signal transduction

Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59

Identification of mouse hepatitis virus papain-like proteinase 2 activity

Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection

Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation

An efficient one-step sitedirected and site-saturation mutagenesis protocol

Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid

Persistent infection promotes cross-species transmissibility of mouse hepatitis virus

A Simplified Procedure for Titrating Hemagglutinating Capacity of Influenza-Virus and the Corresponding Antibody

IRF3 mediates a TLR3/ TLR4-specific antiviral gene program

Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor

Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells

Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitinediting protein A20

Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK

We thank Drs S Vaidya and E Chow (University of California Los Angeles, USA) for their help in setting up critical experimental systems. We greatly thank Dr K Holmes (University of Colorado Health Sciences Center, USA) for sharing with us 17Cl-1 cell line and helping to optimize the protocol to produce high titered MHV-A59 virus stock. We also thank Drs R Baric and L Su (University of North Carolina, USA) for the gift of MHV-A59 and guidance of virus infection. We thank Dr K Lim (National Neuroscience Institute, Singapore) for the gift of Ubi plasmids. We thank Dr M Wathelet (University of Cincinnati College of Medicine, USA) for sharing the nsp3 construct. Also we thank Dr G Gao (Institute of Biophysics, CAS) for providing us with VSV.This research was partly supported by grants from the National Natural Science Foundation of China (30728006) to Genhong Cheng and the National Basic Research Program of MOST (2004BA519A61, 2006CB504300, 2007DFC30190) to Hong Tang.